N5-(1-亚氨基乙基)-L-鸟氨酸盐酸盐(1:1)

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N5-(1-亚氨基乙基)-L-鸟氨酸盐酸盐(1:1)
• 中文别名: 中文名称暂缺
• 英文名称: N₅-(1-iminoethyl)-L-ornithine dihydrochloride
• 英文别名: (2S)-2-amino-5-(1-aminoethylideneamino)pentanoic acid;hydron;chloride
• 化学式: C₇H₁₅N₃O₂*2ClH
• 分子量: 246.137
• InChiKey: JIBZSGQTCBWUKL-RGMNGODLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.02
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  102
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苯甲酰氯 、 N5-(1-亚氨基乙基)-L-鸟氨酸盐酸盐(1:1) 在 碳酸氢钠 、 盐酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 6.0h， 生成 N-α-benzoyl-N5-(1-iminoethyl)-L-ornithine hydrochloride
  参考文献：
  名称：

  WO2007/56389

  摘要：

  公开号：
• 作为产物：
  描述：

  Boc-L-鸟氨酸 在 盐酸 、 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 19.0h， 生成 N5-(1-亚氨基乙基)-L-鸟氨酸盐酸盐(1:1)
  参考文献：
  名称：

  L-N6-(1-Iminoethyl)lysine: A Selective Inhibitor of Inducible Nitric Oxide Synthase

  摘要：

  L-N-6-(1-Iminoethyl)lysine (L-NIL) has been synthesized and is shown to be both a potent and selective inhibitor of mouse inducible nitric oxide synthase (miNOS). L-NIL has an IC50 of 3.3 mu M for miNOS compared to an IC50 of 92 mu M for rat brain constitutive NO indicating that L-NIL is 28-fold more selective for inducible NOS. L-N-5-(1-Iminoethyl)ornithine (L-NIO), which differs from L-NIL by having one less methylene group, has very similar potency for inducible NOS, but lacks selectivity. DL-N-7-(1-Iminoethyl)homolysine was also synthesized and found to be substantially less potent than L-NIL or L-NIO, with intermediate selectivity for inducible NOS, These data suggest that L-NIL may be useful as a selective inhibitor of inducible NOS for determining the role of this enzyme in disease models.

  DOI：

  10.1021/jm00049a007

文献信息

• Amidino derivatives and their use as nitric oxide synthase inhibitors
  申请人：Glaxo Wellcome Inc.

  公开号：US05863931A1

  公开（公告）日：1999-01-26

  Amidino derivatives of formula (I) and salts, and pharmaceutically acceptable esters and amides thereof, in which: R.sup.1 is a C.sub.1-6 straight or branched chain alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group, a C.sub.3-6 cycloalkyl group or a C.sub.3-6 cycloalkylC.sub.1-6 alkyl group; Q is an alkylene, alkenylene or alkynylene group having 3 to 6 carbon atoms and which may optionally be substituted by one or more C.sub.1-3 alkyl groups; a group of formula --(CH.sub.2).sub.p X(CH.sub.2).sub.q -- where p is 2 or 3, q is 1 or 2 and X is S(O).sub.x where x is 0, 1 or 2, O or NR.sup.2 where R.sup.2 is H or C.sub.1-6 alkyl; or a group of formula --(CH.sub.2).sub.r A(CH.sub.2).sub.s -- where r is 0, 1 or 2, s is 0, 1 or 2 and A is a 3 to 6 membered carbocyclic or heterocyclic ring which may optionally be substituted by one or more suitable substituents such as C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halo, nitro, cyano, trifluoro C.sub.1-6 alkyl, amino, C.sub.1-6 alkylamino or diC.sub.1-6 alkylamino; and pharmaceutical formulations containing them are described for use in medicine novel compounds of formula (I) and the preparation of such novel compounds are also disclosed.

  公式（I）的氨基甲酰衍生物及其盐和药学上可接受的酯和酰胺，其中：R.sup.1是C.sub.1-6直链或支链烷基，C.sub.2-6烯基，C.sub.2-6炔基，C.sub.3-6环烷基或C.sub.3-6环烷基C.sub.1-6烷基;Q是具有3到6个碳原子的烷基，烯基或炔基，可以选择地被一个或多个C.sub.1-3烷基取代;公式为--（CH.sub.2）.sub.p X（CH.sub.2）.sub.q--其中p为2或3，q为1或2，X为S（O）.sub.x，其中x为0,1或2，O或NR.sup.2，其中R.sup.2为H或C.sub.1-6烷基;或公式为--（CH.sub.2）.sub.r A（CH.sub.2）.sub.s--其中r为0、1或2，s为0、1或2，A为具有3到6个成员的碳环或杂环，可以选择地被一个或多个适当的取代基取代，如C.sub.1-6烷基，C.sub.1-6烷氧基，羟基，卤素，硝基，氰基，三氟甲基C.sub.1-6烷基，氨基，C.sub.1-6烷基氨基或二C.sub.1-6烷基氨基;并描述了包含它们的药物制剂用于医学的新型化合物的制备。
• Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions
  申请人：——

  公开号：US20040220113A1

  公开（公告）日：2004-11-04

  A novel method of treating and preventing diseases is provided. In particular, compositions and methods of blocking diseases associated with aberrant levels of nitric oxide and facilitated by a serine proteolytic (SP) activity are disclosed, which consist of administering to a subject a therapeutically effective amount of a compound having a serine protease inhibitory activity. Among effective compounds are &agr; 1 -antitrypsin and synthetic drugs mimicking some or all of the actions of &agr; 1 -antitrypsin.

  本文提供了一种治疗和预防疾病的新方法。特别是，本发明公开了阻断与一氧化氮水平异常相关并由丝氨酸蛋白酶（SP）活性促进的疾病的组合物和方法，其中包括向受试者施用治疗有效量的具有丝氨酸蛋白酶抑制活性的化合物。其中有效的化合物有 1 -抗胰蛋白酶和模拟 &agr; 1 的部分或全部作用的合成药物； 1 -抗胰蛋白酶。
• Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
  申请人：——

  公开号：US20040220242A1

  公开（公告）日：2004-11-04

  A novel method of treating and preventing diseases is provided. In particular, compositions and methods of blocking diseases associated with aberrant levels of nitric oxide and facilitated by a serine proteolytic (SP) activity are disclosed, which consist of administering to a subject a therapeutically effective amount of a compound having a serine protease inhibitory activity. Among effective compounds are &agr; 1 -antitrypsin and synthetic drugs mimicking some or all of the actions of &agr; 1 -antitrypsin.

  本文提供了一种治疗和预防疾病的新方法。特别是，本发明公开了阻断与一氧化氮水平异常相关并由丝氨酸蛋白酶（SP）活性促进的疾病的组合物和方法，其中包括向受试者施用治疗有效量的具有丝氨酸蛋白酶抑制活性的化合物。其中有效的化合物有 1 -抗胰蛋白酶和模拟 &agr; 1 的部分或全部作用的合成药物； 1 -抗胰蛋白酶。
• AMIDINO DERIVATIVES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0618898B1

  公开（公告）日：1999-04-07
• METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE
  申请人：Tyers Mike

  公开号：US20090076019A1

  公开（公告）日：2009-03-19

  A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.